Adverse events (serious) · carpal tunnel syndrome
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Serious adverse events · adults with chronic neuropathic pain
1 finding from 1 review
Serious adverse events · children with acute postoperative pain
1 finding from 1 review
Serious adverse events · children with bronchiectasis
Macrolides showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · adults with bronchiectasis
Macrolides showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · post‐prostatectomy erectile dysfunction (short‐term)
Scheduled PDE5I may leads to lower serious adverse events compared with on demand placebo or no treatment (low certainty).
1 finding from 1 review
Serious adverse events · cancer patients
Olanzapine showed no clear difference in serious adverse events compared with placebo/no treatment (low certainty).
1 finding from 1 review
RR 2.46 [0.48, 12.55]
Studies not reported
Low
Serious adverse events · Patients with active Crohn's disease
It is very uncertain whether cannabis oil (5% cannabidiol sublingual oil) changes serious adverse events compared with placebo oil (very low certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with active UC
Cannabidiol showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Methotrexate showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Interferon beta‐1a showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Patients with collagenous colitis
Mesalamine showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Patients with collagenous colitis
It is very uncertain whether budesonide changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events · adults with neuropathic pain
1 finding from 1 review
Serious adverse events · patients with rheumatoid arthritis in adults
Certolizumab pegol 200 mg sc (with or without MTX) leads to higher serious adverse events compared with placebo (with or without MTX) (high certainty).
1 finding from 1 review
Serious adverse events · adults with neuropathic pain
1 finding from 1 review
Serious adverse events · Adults with plantar heel pain¹
1 finding from 1 review